Sei Investments Co. Has $8.78 Million Position in Amneal Pharmaceuticals, Inc. $AMRX

Sei Investments Co. increased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 26.3% in the first quarter, Holdings Channel reports. The institutional investor owned 706,681 shares of the company’s stock after buying an additional 147,249 shares during the period. Sei Investments Co.’s holdings in Amneal Pharmaceuticals were worth $8,784,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Artemis Investment Management LLP acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $1,574,000. Louisiana State Employees Retirement System acquired a new position in Amneal Pharmaceuticals during the first quarter worth $936,000. Tudor Investment Corp ET AL acquired a new position in Amneal Pharmaceuticals during the third quarter worth $921,000. HighTower Advisors LLC bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at $1,121,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Amneal Pharmaceuticals by 30.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,480,172 shares of the company’s stock valued at $18,739,000 after buying an additional 344,373 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals News Roundup

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations. Amneal reported revenue of approximately $796 million, GAAP net income of $58 million, adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus and up from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $3.1 billion to $3.2 billion, compared with a prior outlook near $3.1 billion, suggesting continued confidence in demand and operating performance. AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
• Positive Sentiment: Debt repricing should reduce interest expense. The company completed a July debt repricing, which is expected to lower borrowing costs and support future earnings and cash flow. Amneal Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: EPS guidance was broadly in line with consensus. Amneal forecast 2026 EPS of $0.96 to $1.06 versus the $0.97 consensus estimate. While the midpoint is slightly above expectations, the range does not represent a major upward revision.
• Negative Sentiment: Investors may be taking profits after the earnings-driven rally. The strong quarterly beat and revenue outlook improvement were likely already reflected in the stock after its recent advance, leaving limited upside when full-year earnings guidance was only modestly better than expectations. Amneal beats expectations in strong Q2 2026

Insider Activity

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 17.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

AMRX has been the topic of several analyst reports. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. UBS Group lifted their target price on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. The Goldman Sachs Group reiterated a “buy” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a report on Friday. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Finally, Barclays raised their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Amneal Pharmaceuticals Stock Down 1.0%

Shares of AMRX stock opened at $18.32 on Friday. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.59 and a current ratio of 2.20. The firm’s 50-day moving average is $16.23 and its 200-day moving average is $14.26. The stock has a market cap of $5.84 billion, a price-to-earnings ratio of 37.39 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a 52-week low of $7.66 and a 52-week high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The business had revenue of $722.52 million during the quarter. Sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.